首页> 外文期刊>The Journal of Pharmacology and Experimental Therapeutics: Official Publication of the American Society for Pharmacology and Experimental Therapeutics >Interactions of Cocaine with Dopamine Uptake Inhibitors or Dopamine Releasers in Rats Discriminating Cocaine
【24h】

Interactions of Cocaine with Dopamine Uptake Inhibitors or Dopamine Releasers in Rats Discriminating Cocaine

机译:可卡因与歧视可卡因的大鼠中多巴胺摄取抑制剂或多巴胺释放剂的相互作用

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Several dopamine (DA) indirect agonists have been proposed as potential medications for treating cocaine abuse.The objective of the present study was to quantify the interactions among cocaine and DA uptake inhibitors or DA releasers to better understand how these drugs may be working when administered in combination.The DA uptake inhibitors GBR 12909 [1-{2-[bis-(4-fluorophenyl)methoxy]-ethyl}-4-(3-phenylpropyl)piperazine],WIN 35,428 [2beta-carbo-methoxy-3beta-(4-fluorophenyl)tropane],methylphenidate,in-datraline,nomifensine,and mazindol and DA releasers methamphetamine,d-amphetamine,methcathinone,cathi-none,fencamfamine,and phentermine were examined alone and in combination with cocaine in rats trained to discrimi-nate cocaine (10 mg/kg i.p.) from saline injections.All of the DA indirect agonists dose-dependently substituted for cocaine and shifted the cocaine dose-effect curve leftward.Isobolographic analysis indicated the interactions were generally additive,although both methamphetamine and d-am-phetamine were quantitatively determined to be more potent than DA uptake inhibitors in shifting the cocaine dose-effect function to the left.The potential of d-amphetamine as an effective treatment for cocaine abuse and negative clinical results with dopamine uptake inhibitors suggest that differences in shifts in dose-effect curves should be further examined with emerging clinical data as a predictive index of potential treatments for cocaine abuse.
机译:已经提出了几种多巴胺(DA)间接激动剂作为治疗可卡因滥用的潜在药物。本研究的目的是量化可卡因与DA吸收抑制剂或DA释放剂之间的相互作用,以更好地了解这些药物在静脉内给药时如何发挥作用。 DA吸收抑制剂GBR 12909 [1- {2- [双-(4-氟苯基)甲氧基]-乙基} -4-(3-苯基丙基)哌嗪],WIN 35,428 [2beta-羰基-甲氧基-3beta-( [4-氟苯基] [tropophane],哌醋甲酯,萘达林,吗啡,以及mazindol和DA释放剂甲基苯丙胺,d-苯异丙胺,甲卡西酮,cathi-none,芬卡明和芬特明分别与可卡因组合使用,对受过歧视的大鼠进行了检查从盐水注射中提取可卡因(10 mg / kg ip)。所有DA间接激动剂均剂量依赖性地替代可卡因,并向左移动可卡因的剂量效应曲线。等效线谱分析表明,相互作用通常是累加的,尽管两种方法都相同定量确定了胺和d-苯丙胺在将可卡因剂量效应功能向左转移方面比DA吸收抑制剂更有效.d-苯丙胺作为可卡因滥用的有效治疗方法的潜力以及多巴胺摄入的临床阴性抑制剂提示应根据新兴的临床数据进一步研究剂量效应曲线变化的差异,以此作为可卡因滥用潜在疗法的预测指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号